JW Pharmaceutical (A001060) Stock Overview
Manufactures and sells medicines and medical supplies in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for A001060 from our risk checks.
A001060 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
JW Pharmaceutical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩27,100.00 |
| 52 Week High | ₩27,800.00 |
| 52 Week Low | ₩19,600.00 |
| Beta | 1 |
| 1 Month Change | 9.27% |
| 3 Month Change | 20.18% |
| 1 Year Change | 16.56% |
| 3 Year Change | 39.91% |
| 5 Year Change | -10.10% |
| Change since IPO | 718.27% |
Recent News & Updates
Recent updates
JW Pharmaceutical's (KRX:001060) Upcoming Dividend Will Be Larger Than Last Year's
Dec 26
JW Pharmaceutical's (KRX:001060) Solid Earnings May Rest On Weak Foundations
Nov 23JW Pharmaceutical (KRX:001060) Seems To Use Debt Rather Sparingly
Aug 07JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality
Mar 21Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?
Apr 08How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?
Mar 13Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.
Jan 19
Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend
Dec 24Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?
Nov 30Shareholder Returns
| A001060 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 3.4% | -0.1% | 2.2% |
| 1Y | 16.6% | 38.3% | 65.7% |
Return vs Industry: A001060 underperformed the KR Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: A001060 underperformed the KR Market which returned 67.7% over the past year.
Price Volatility
| A001060 volatility | |
|---|---|
| A001060 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A001060 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A001060's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 1,068 | Young-Sub Shin | www.jw-pharma.co.kr |
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment.
JW Pharmaceutical Corporation Fundamentals Summary
| A001060 fundamental statistics | |
|---|---|
| Market cap | ₩620.94b |
| Earnings (TTM) | ₩57.97b |
| Revenue (TTM) | ₩764.21b |
Is A001060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A001060 income statement (TTM) | |
|---|---|
| Revenue | ₩764.21b |
| Cost of Revenue | ₩411.75b |
| Gross Profit | ₩352.45b |
| Other Expenses | ₩294.49b |
| Earnings | ₩57.97b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.53k |
| Gross Margin | 46.12% |
| Net Profit Margin | 7.59% |
| Debt/Equity Ratio | 12.7% |
How did A001060 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 05:43 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JW Pharmaceutical Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Hyun-Su Gwak | Shinhan Investment Corp. |
| Jiha Kim | Shinhan Investment Corp. |